Reading the tape
NASDAQ: GPCR
Structure Therapeutics Inc.
Healthcare · Biotechnology
Market Cap
$2.48B
52w High
$94.90
52w Low
$15.80
P/E
-18.04
Volume
806.22K
Outstanding Shares
57.57M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 56.23%FCF (TTM): -91.49%
What changed
The stock rose 56.23% over the last year. Free cash flow declined 91.49% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
CEORaymond C. Stevens
SectorHealthcare
IndustryBiotechnology
Employees163
IPO dateFeb 3, 2023
Valuation
Forward P/E—
EV/EBITDA-24.30
Enterprise value$3.32B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-9.31%▲34.27%vs FY2024
Analyst consensus
RatingBuy
Target price$114.75▲166.61%
14
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.39 · Revenue est $10M
View